High antibody and cellular responses induced to HIV-1 clade C envelope following DNA vaccines delivered by electroporation

Vaccine

Volumn 29, Issue 39, 2011, Pages 6763-6770

  Yin, Jiangmei ^a   Dai, Anlan ^a   LeCureux, Jonathan ^a   Arango, Tatiana ^a   Kutzler, Michele A ^b   Yan, Jian ^a   Lewis, Mark G ^c   Khan, Amir ^d   Sardesai, Niranjan Y ^d   Montefiore, David ^e   Ruprecht, Ruth ^f   Weiner, David B ^a   Boyer, Jean D ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^c BIOQUAL INC   (United States)

^d Inovio Pharmaceuticals   (United States)

^e DUKE UNIVERSITY   (United States)

^f HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Clade C; DNA vaccine; RANTES; SHIV

Indexed keywords

CLADE C PROTEIN; DNA VACCINE; GAMMA INTERFERON; IMMUNOLOGICAL ADJUVANT; PLASMID DNA; RANTES; SIVGAG PROTEIN; SIVPOL PROTEIN; UNCLASSIFIED DRUG; VIRUS ENVELOPE PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ANTIBODY TITER; ANTIGEN SPECIFICITY; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CLADISTICS; CONTROLLED STUDY; DNA IMMUNIZATION; EFFECTOR CELL; ELECTROPORATION; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME LINKED IMMUNOSPOT ASSAY; GENE DELIVERY SYSTEM; GENE EXPRESSION; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOSTIMULATION; INTERFERON PRODUCTION; LYMPHOCYTE PROLIFERATION; NONHUMAN; PRIORITY JOURNAL; RHESUS MONKEY; SIMIAN IMMUNODEFICIENCY VIRUS; T LYMPHOCYTE SUBPOPULATION; VIRUS LOAD; VIRUS REPLICATION; VIRUS STRAIN;

ADJUVANTS, IMMUNOLOGIC; AIDS VACCINES; ANIMALS; ANTIBODY FORMATION; CHEMOKINE CCL5; ELECTROPORATION; ENZYME-LINKED IMMUNOSPOT ASSAY; GENES, ENV; GENES, GAG; GENES, POL; HIV ANTIBODIES; HIV INFECTIONS; HIV-1; HUMANS; IMMUNITY, CELLULAR; IMMUNITY, HUMORAL; IMMUNOLOGIC MEMORY; INTERFERON-GAMMA; MACACA MULATTA; NEUTRALIZATION TESTS; SIMIAN IMMUNODEFICIENCY VIRUS; T-LYMPHOCYTES; VACCINATION; VACCINES, DNA; VIRAL LOAD;

EID: 80052285787     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.12.055     Document Type: Article

References (24)

1. Barouch D.H. Challenges in the development of an HIV-1 vaccine. Nature 2008, 455:613-619.
2. Graham B.S., Koup R.A., Roederer M., Bailer R.T., Enama M.E., Moodie Z., et al. Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 DNA candidate vaccine. J Infect Dis 2006, 194:1650-1660.
3. Barouch D.H., Santra S., Schmitz J.E., Kuroda M.J., Fu T.M., Wagner W., et al. Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination. Science 2000, 290:486-492.
4. Chong S.Y., Egan M.A., Kutzler M.A., Megati S., Masood A., Roopchard V., et al. Comparative ability of plasmid IL-12 and IL-15 to enhance cellular and humoral immune responses elicited by a SIVgag plasmid DNA vaccine and alter disease progression following SHIV(89. 6P) challenge in rhesus macaques. Vaccine 2007, 25:4967-4982.
5. Luckay A., Sidhu M.K., Kjeken R., Megati S., Chong S.Y., Roopchand V., et al. Effect of plasmid DNA vaccine design and in vivo electroporation on the resulting vaccine-specific immune responses in rhesus macaques. J Virol 2007, 81:5257-5269.
6. Liu J., Kjeken R., Mathiesen I., Barouch D.H. Recruitment of antigen-presenting cells to the site of inoculation and augmentation of human immunodeficiency virus type 1 DNA vaccine immunogenicity by in vivo electroporation. J Virol 2008, 82:5643-5649.
7. Hirao L.A., Wu L., Khan A.S., Hokey D.A., Yan J., Dai A., et al. Combined effects of IL-12 and electroporation enhances the potency of DNA vaccination in macaques. Vaccine 2008, 26:3112-3120.
8. Prud'homme G.J., Glinka Y., Khan A.S., Draghia-Akli S R. Electroporation-enhanced nonviral gene transfer for the prevention or treatment of immunological, endocrine and neoplastic diseases. Curr Gene Ther 2006, 6:243-273.
9. Frauenschuh A., DeVico A.L., Lim S.P., Gallo R.C., Garzino-Demo A. Differential polarization of immune responses by co-administration of antigens with chemokines. Vaccine 2004, 23:546-554.
10. Kim J.J., Nottingham L.K., Sin J.I., Tsai A., Morrison L., Oh J., et al. CD8 positive T cells influence antigen-specific immune responses through the expression of chemokines. J Clin Invest 1998, 102:1112-1124.
11. Waterman P.M., Kitabwalla M., Hatfield G.S., Evans P.S., Lu Y., Tikhonov I., et al. Effects of virus burden and chemokine expression on immunity to SHIV in nonhuman primates. Viral Immunol 2004, 17:545-557.
12. Xin K.Q., Lu Y., Hamajima K., Fukushima J., Yang J., Inamura K., et al. Immunization of RANTES expression plasmid with a DNA vaccine enhances HIV-1-specific immunity. Clin Immunol 1999, 92:90-96.
13. Hadida F., Vieillard V., Autran B., Clark-Lewis I., Baggiolini M., Debre P. HIV-specific T cell cytotoxicity mediated by RANTES via the chemokine receptor CCR3. J Exp Med 1998, 188:609-614.
14. Yan J., Hokey D.A., Morrow M.P., Corbitt N., Harris K., Harris D., et al. Novel SIVmac DNA vaccines encoding Env Pol and Gag consensus proteins elicit strong cellular immune responses in cynomolgus macaques. Vaccine 2009, 27:3260-3266.
15. Li M., Gao F., Mascola J.R., Stamatatos L., Polonis V.R., Koutsoukos M., et al. Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies. J Virol 2005, 79:10108-10125.
16. Montefiori D.C. Evaluating neutralizing antibodies against HIV, SIV and SHIV in luciferase reporter gene assays. Current protocols in immunology 2004, John Wiley & Sons. J.E. Coligan, A.M. Kruisbeek, D.H. Margulies, E.M. Shevach, W. Strober, R. Coico (Eds.).
17. Song R.J., Chenine A.-L., Rasmussen R.A., Ruprecht C.R., Mirshahidi S., Grisson R.D., et al. Molecularly cloned SHIV-1157pd3N4: a highly replication competent, mucosally transmissible R5 simian-human-immunodeficiency virus encoding HIV clade C env. J Virol 2006, 80:8729-8738.
18. Siddappa N.B., Watkins J.D., Wassermann K.J., Song R., Wang W., Kramer V.G., Lakhashe S., Santosuosso M., Poznansky M.C., Novembre F.J., Villinger F., Else J.G., Montefiori D.C., Rasmussen R.A., Ruprecht R.M. R5 clade C SHIV strains with tier 1 or 2 neutralization sensitivity: tools to dissect Env evolution and to develop AIDS vaccines in primate models. PLoS One 2010, 5:e11689.
19. Romano J.W., Shurtliff R.N., Dobratz E., Gibson A., Hickman K., Markham P.D., et al. Quantitative evaluation of simian immunodeficiency virus infection using NASBA technology. J Virol Methods 2000, 86:61-70.
20. Sin J., Kim J.J., Pachuk C., Satishchandran C., Weiner D.B. DNA vaccines encoding interleukin-8 and RANTES enhance antigen-specific Th1-type CD4(+) T-cell-mediated protective immunity against herpes simplex virus type 2 in vivo. J Virol 2000, 74:11173-11180.
21. Shimizu Y., Inaba K., Kaneyasu K., Ibuki K., Himeno A., Okoba M., et al. A genetically engineered live-attenuated simian-human immunodeficiency virus that co-expresses the RANTES gene improves the magnitude of cellular immunity in rhesus macaques. Virology 2007, 361:68-79.
22. Kutzler M.A., Weiner D.B. DNA vaccines: ready for prime time?. Nat Rev Genet 2008, 9:776-788.
23. Abdulhaqq S.A., Weiner D.B. DNA vaccines: developing new strategies to enhance immune responses. Immunol Res 2008, 42:219-232.
24. Bodles-Brakhop A.M., Draghia-Akli R. DNA vaccination and gene therapy: optimization and delivery for cancer therapy. Expert Rev Vaccines 2008, 7:1085-1101.